Information Provided By:
Fly News Breaks for November 17, 2015
CLVS
Nov 17, 2015 | 06:44 EDT
WallachBeth analyst Bob Ai downgraded Clovis Oncology to Hold citing the "much lower" confirmed response rate of rociletinib. The analyst cut his price target for the stock to $30 from $135. Goldman Sachs this morning also downgraded Clovis.
News For CLVS From the Last 2 Days
There are no results for your query CLVS